Neurology:阿尔茨海默病的神经精神症状

2017-04-18 zhangfan MedSci原创

临床阿尔茨海默病伴神经精神症状患者主要表现为睡眠行为障碍与情绪不稳定

研究人员近日就识别与临床阿尔茨海默病(AD)相关神经精神症状(NPS)的局部脑代谢功能障碍开展研究。

研究招募了115名认知正常的参与者,通过使用[18F] PET和脑脊液磷酸化tau蛋白的生物标志物分析分别编入临床AD组(淀粉样蛋白和tau蛋白病变)、无症状的AD风险组(淀粉样蛋白或tau蛋白病变)以及对照组(无淀粉样蛋白和tau蛋白病变),通过回归和基于个体因素的回归模型评估NPS与2年脑代谢变化之间的关系。

研究发现,只有临床前AD组患者NPS得分较高,在后扣带回皮质、腹内侧前额叶皮层和右前脑岛有较高的[18F]摄取。只有在临床前AD组患者2年后的后扣带回皮质功能衰退得分较高。睡眠行为障碍、夜间易怒和情绪不稳定是NPS代谢功能障碍的主要表现。

临床阿尔茨海默病伴神经精神症状患者主要表现为睡眠行为障碍与情绪不稳定,是由于阿尔茨海默病进程中边缘网络代谢功能短暂异常以及后续后扣带回皮质代谢降低造成的。这说明神经精神症状是阿尔茨海默病临床病理生理学的早期表现。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816760, encodeId=35961816e6083, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Dec 07 04:01:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999884, encodeId=d036199988420, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 11 07:01:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032037, encodeId=3bf0203203e4b, content=<a href='/topic/show?id=07c4e6558d5' target=_blank style='color:#2F92EE;'>#精神症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76558, encryptionId=07c4e6558d5, topicName=精神症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun Oct 01 17:01:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817783, encodeId=1137181e783d6, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 30 12:01:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470137, encodeId=d5b114e0137de, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Apr 20 03:01:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816760, encodeId=35961816e6083, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Dec 07 04:01:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999884, encodeId=d036199988420, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 11 07:01:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032037, encodeId=3bf0203203e4b, content=<a href='/topic/show?id=07c4e6558d5' target=_blank style='color:#2F92EE;'>#精神症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76558, encryptionId=07c4e6558d5, topicName=精神症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun Oct 01 17:01:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817783, encodeId=1137181e783d6, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 30 12:01:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470137, encodeId=d5b114e0137de, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Apr 20 03:01:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
    2017-10-11 yinhl1978
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816760, encodeId=35961816e6083, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Dec 07 04:01:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999884, encodeId=d036199988420, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 11 07:01:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032037, encodeId=3bf0203203e4b, content=<a href='/topic/show?id=07c4e6558d5' target=_blank style='color:#2F92EE;'>#精神症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76558, encryptionId=07c4e6558d5, topicName=精神症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun Oct 01 17:01:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817783, encodeId=1137181e783d6, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 30 12:01:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470137, encodeId=d5b114e0137de, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Apr 20 03:01:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816760, encodeId=35961816e6083, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Dec 07 04:01:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999884, encodeId=d036199988420, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 11 07:01:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032037, encodeId=3bf0203203e4b, content=<a href='/topic/show?id=07c4e6558d5' target=_blank style='color:#2F92EE;'>#精神症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76558, encryptionId=07c4e6558d5, topicName=精神症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun Oct 01 17:01:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817783, encodeId=1137181e783d6, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 30 12:01:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470137, encodeId=d5b114e0137de, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Apr 20 03:01:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816760, encodeId=35961816e6083, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Dec 07 04:01:00 CST 2017, time=2017-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1999884, encodeId=d036199988420, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Wed Oct 11 07:01:00 CST 2017, time=2017-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032037, encodeId=3bf0203203e4b, content=<a href='/topic/show?id=07c4e6558d5' target=_blank style='color:#2F92EE;'>#精神症状#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76558, encryptionId=07c4e6558d5, topicName=精神症状)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sun Oct 01 17:01:00 CST 2017, time=2017-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817783, encodeId=1137181e783d6, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sun Jul 30 12:01:00 CST 2017, time=2017-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470137, encodeId=d5b114e0137de, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Thu Apr 20 03:01:00 CST 2017, time=2017-04-20, status=1, ipAttribution=)]

相关资讯

痴呆、健忘、阿尔茨海默病都有啥区别?

AD和痴呆、健忘有什么区别吗?今天小编就对这一个问题进行解答。一般来说,老年人在进入60岁以后,其记忆能力可能会有轻度的下降,但是这种改变只是暂时的,偶尔会发生,而且过段时间忘记了的东西又会记起来,这就是老年人健忘,是一种正常现象。而痴呆的英文单词是“dementia”,它是一种疾病,这种疾病的主要表现是:在清醒的情况下(不是在睡觉的时候),病人出现记忆力的减退(如记不起今天早上吃了什么,记不

MOL PSYCHIATR: 阿尔茨海默病相关基因座遗传易感性的评估

包括阿尔茨海默病(AD)和其他神经变性病症在内的Tau病变都是神经原纤维缠结(NFTs)的原因。随着年龄的增长,大脑中也会积累神经纤维缠结(NFT)。NFT的积累被认为与AD的认知衰退密切相关。Tau蛋白病理是阿尔茨海默症(AD)的一个重要特征。本研究对影响Tau蛋白聚集的关键基因进行了阐述。

阿尔茨海默病会遗传吗?

一、什么是家族性阿尔茨海默病(Familial Alzheimer’s Disease, FAD)家族性阿尔茨海默病(FAD)是指家族中有连续两代或者两代以上的成员罹患阿尔茨海默病,可追溯的家族成员中有三个或者三个以上患者,且发病年龄早于60岁,占AD患者的5%左右。国外流行病学统计,FAD的患病约为5.3 /100,000。据此估计,中国的家族性AD患者将在6万~10万。二、FAD的特征相比

吃糖多了会痴呆?--- 葡萄糖在阿尔茨海默病中修饰氧化巨噬细胞迁移抑制因子

葡萄糖和葡萄糖代谢物能够通过称为糖化的非酶反应有害的改变蛋白质,其与阿尔茨海默病(AD)的病理学相关,并且是糖尿病诱导的高血糖症的特征之一。

Mol Psychiatry: PTPRD位点在神经原纤维缠结的敏感性中的作用

NFT积累被认为与AD的认知衰退密切相关。PTPRD是蛋白酪氨酸磷酸酶(PTP)家族成员。鸡和果蝇实验表明,PTPRD基因可以促进神经轴突生长、调节神经元的轴突导向。已经有报道显示了这个基因可有多可变剪接转录变体。研究中小鼠和果蝇实验所显示的PTPRD与记忆紊乱和Tau的病理恶化相关,表明了调节PTPRD的活动水平可以降低个体的Tau病理现象。

一种治疗阿尔茨海默症的“ASTROSTEM”自体脂肪干细胞疗法

2016年11月23日,礼来(Lilly)研究开发长达27年,投入近30亿美元研发的抗阿尔兹海默症新药Solanezumab在Ⅲ期试验中宣告失败。3个月后,2017年情人节(2月14日)那天,默沙东的阿尔兹海默症新药Verubecestat也被告知“几乎不可能得到一个积极的临床结果”而终止其临床试验,这给业内万众瞩目的新药研发领域泼了好大一盆冷水。那么如果我们换种方式,用干细胞来治疗是否可行?3月